Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction by Wang, J. et al.
Existence of transient functional double-stranded
DNA intermediates during recombinant
AAV transduction
Jinhui Wang*, Jing Xie*, Hui Lu*, Lingxia Chen*, Bernd Hauck*, Richard Jude Samulski†, and Weidong Xiao*‡
*Department of Pediatrics, University of Pennsylvania Health Center, Children’s Hospital of Philadelphia, Philadelphia, PA 19104; and †Department of
Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599
Edited by Thomas E. Shenk, Princeton University, Princeton, NJ, and approved July 2, 2007 (received for review March 24, 2007)
Previous studies have documented that 0.11% of input recom-
binant adeno-associated virus (rAAV) vectors could be stabilized
and lead to transgene expression. To characterize the steps involv-
ing massive AAV DNA loss, we designed an‘‘AAV footprinting’’
strategy that can track newly formed AAV dsDNA genomes. This
strategy is based on an ROSA26R mouse model or cell line that
carries a lacZ gene flanked by two loxP sites. When it is transduced
by a rAAV vector carrying the Cre recombinase, the lacZ gene can
be activated and remain active even when rAAV genomes are later
lost. By using this sensitive AAV footprinting technique, we con-
firmed the existence of transient AAV dsDNA that went undetec-
ted by conventional DNA methods. Although these dsDNA inter-
mediates could be efficiently formed in almost every cell and were
competent for mRNA transcription and protein synthesis in vivo,
they got lost continuously. Only a small fraction was eventually
stabilized for sustained gene expression. Although both rAAV2
and rAAV8 can potentially have similar levels of dsDNA formation,
AAV8 dsDNA was formed much faster than that of AAV2, which
explains why rAAV8 is more efficient than rAAV2 in transducing
the liver. Collectively, our studies suggested that rather than
receptor binding, viral entry, and ssDNA to dsDNA conversion, the
instability of newly formed AAV dsDNA was the primary contrib-
uting factor for the low rAAV transduction efficacy. The uncoating
step significantly influenced the stability of AAV transient dsDNA.
The identification of transient AAV dsDNA provided a new path-
way for improving rAAV transduction.
adeno-associated virus  DNA stability  gene therapy  vector  ROSA26R
Adeno-associated virus (AAV) is a nonpathogenic and replica-tion-defective human parvovirus with a single-stranded (ss)
DNA genome (1). AAV-based recombinant vectors (rAAVs) have
been studied extensively in animal models, and the long-term
transgene expression from rAAV vectors has been well docu-
mented (2–4). One distinct feature of rAAV transduction is the lack
of T cell mediated immune responses to the vector and transgene
in animal experiments (5, 6). To date, rAAV is the only ssDNA
vector being tested in human clinical trials (7–10).
For long-term transgene expression from rAAV vectors, rAAV
must successfully avoid degradation in the endosome and release its
ssDNA genomes (11–17). The ssDNA genome will then be an-
nealed or converted into the ds form (18–20). The ds form can serve
as a template for RNA transcription, which can subsequently lead
to translation of transgene products. Compared with other vectors,
rAAV vectors posses a unique expression profile. For AAV sero-
type 2 (AAV2), after administration in vivo, significant transgene
expression is not observed until 1–2 weeks, reaching a plateau at
week 4–6. The slow rise of rAAV transduction was thought to be
limited by the conversion from ssDNA to dsDNA (18–20). How-
ever, recent studies suggested that this expression delay is primarily
the result of the uncoating efficacy of vector genomes in liver, which
determines the ability of conversion from ssDNA to dsDNA (21,
22). Our previous studies of tracking free ssDNA genomes revealed
that conversion from released ssDNA genome to dsDNA genome
was a rather fast reaction because free ssDNA genomes could not
be observed by a specially designed BrdU labeling technique (23).
Therefore, steps before uncoating or after dsDNA formation may
be the deciding factors for rAAV transduction efficacy.
Another unanswered issue is whether the initial dsDNAs formed
after uncoating are stable forms leading to long-term gene expres-
sion. The circular intermediates of rAAV transduction have been
studied extensively and were shown to be abundant after rAAV
vector administration (24–28). Circular DNAs were eventually
converted into high-molecular weight concatemers and were pre-
sumably stabilized. There are two major categories of stabilized
AAV genomes that can be detected months after rAAV transduc-
tion: extrachromosomal concatemers and integrated AAV ge-
nomes (29, 30). Although wild-type AAV frequently underwent
site-specific integration into human chromosome 19, similar inte-
grations by rAAV were infrequent (31, 32). Even though a variety
of integration junctions between rAAV and the host chromosome
have been recovered, no evidence was found to support that these
integrants are the primary sources for transgene expression. In-
stead, extrachromosomal concatemers were primarily responsible
for stable hepatocyte transduction (32).
Many newly discovered AAV serotypes showed improved per-
formance in transduction over AAV2 (33–37). The most notable
differences are AAV1 and AAV6 in the muscle and AAV8 in the
liver. Because the apparent differences among these serotypes are
the capsid protein, viral entry and cellular receptors have been
thought to be the primary determining factor for transduction
efficacy. In this current work, we take advantage of ROSA26R
mouse generated by Soriano (38) and use it to track the timing of
AAV dsDNA conversion and the stability of newly formed AAV
dsDNA genomes. In contrast to common belief, our results sug-
gested that the amount of dsDNA formed was much more than
what was observed previously. The timing of dsDNA formation,
which was affected by AAV capsid rather than the total amount of
dsDNA formed during rAAV transduction, is the critical determi-
nant of its transduction efficacy.
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Results
Differential Tracking of Stabilized rAAV Genomes and Transient
Functional AAV dsDNA. We speculate that not all formed AAV
dsDNAs are stabilized and contributing to the long-term rAAV
transduction. The most intuitive approach to address this problem
is to compare the total amount of AAV dsDNA formed after
rAAV infection with the total amount of dsDNA remaining after
long-term rAAV transduction. In reality, it is virtually impossible to
measure the total amount of dsDNA formed. The main reason is
that AAV uncoating/intracellular processing is a slow process
lasting for weeks, and the degradation of these monomers occurs
simultaneously with synthesis. It is also difficult to define the time
point at which the uncoating process and dsDNA formation are
completed. A potential way to assess the loss of dsDNA is to track
the cells that have been transduced with rAAV genomes but then
lose dsDNA over time. However, it is equally difficult to identify
these cells both in vivo and in vitro. To overcome this difficulty, we
designed a strategy to estimate the cells that have been infected with
rAAV genomes, harbored dsDNA genomes, and expressed trans-
gene products but gradually lost their rAAV genomes. The key for
this strategy is to imprint the cells that once harbored AAV dsDNA.
Our strategy takes advantage of loxP-lacZ cell lines and mice, which
carry an integrated inactive lacZ gene. This lacZ gene is under the
control of loxP elements. When the stop element for translation is
removed by Cre recombinase (Cre)-induced recombination, this
lacZ gene becomes activated and leads to the expression of -
galactosidase, which can be detected by X-Gal staining. Because the
excision is very efficient and the maintenance of LacZ expression
does not require continuous expression of Cre protein, the specially
designed rAAV can therefore be used to distinguish the host cells
that have rAAV genomes from those that have been transduced by
rAAV vectors but lose rAAV genomes. For tracking stabilized
rAAV genomes, we used human placenta alkaline phosphatase
(ALP) as the reporter gene. To avoid the complication of transgene
inactivation, we chose a constitutive promoter, -actin promoter
with CMV enhancer (CB). The constitutive expression from this
promoter has been demonstrated on many occasions. This strategy
is illustrated in Fig. 1.
As shown in Fig. 1A, both AAV-CB-ALP and AAV-CB-cre
vector DNA are similar in size. After ALP and cre vectors transduce
the target cells and start to express ALP and Cre, there are two
main consequences. As shown in Fig. 1B, the Cre expression may
cause host chromosome rearrangement and activate the lacZ gene,
which can be detected by LacZ staining. Once the lacZ gene is
activated, it will remain active regardless of the status of AAV-cre
genomes (Fig. 1C). However, ALP expression requires the presence
of dsAAV-ALP genome. Thus, the transient AAV dsDNA, rep-
resented by LacZ expression, and stabilized genomes, represented
by ALP expression, can be readily monitored. To rule out the
potential activation of loxP recombination by rAAV itself, AAV-
CB-EGFP was tested both in vitro and in vivo. There was no LacZ
expression activated by the AAV-GFP vectors, confirming that
lacZ can only get activated with the expression of Cre [supporting
information (SI) Fig. 7].
Characterization of Transient AAV dsDNA Intermediates Formation in
Vitro. To assess rAAV genomes in vitro, we established the C2lacZ
cell line. In C2lacZ cells, a lacZ reporter gene has been genetically
engineered into the genomic DNA in a way that a loxP-flanked stop
sequence prevents LacZ expression. When Cre is expressed in the
cell, it mediates recombination between the loxP sites and splices
out the stop sequence, thereby allowing constitutive LacZ
expression in that cell (Fig. 1B). Because C2lacZ is derived from
a mouse myoblast cell line, the cell division can be controlled by
differentiation.
We infected C2lacZ cells with equal amounts of AAV-CB-ALP
and AAV-CB-cre and monitored for ALP and LacZ expression. As
shown in Fig. 2A, in nondividing cells, the amount of ALP- or
LacZ-positive cells kept increasing after infection. The increasing
profiles of ALP-positive cells and LacZ-positive cells were similar
to each other. At day 1, there was no LacZ expression detected,
which was probably caused by delay of the recombination reaction.
Cre expression took 18–24 h after rAAV infection, and it
corresponded to the lag of LacZ detection. At day 7, both ALP- and
LacZ-positive cells were close to their peak levels. In contrast, it
showed a very different ALP- and LacZ-staining profile in the
dividing cells. The amount of LacZ-positive cells, representing all
functional dsDNA synthesized, continued to increase. However, the
number of ALP-positive cells was not only significantly less than
LacZ-positive cells but also exhibited a peak at days 3–5 before
falling off. Because ALP expression requires the presence of AAV
dsDNA, whereas LacZ expression can be derived from transient
expression from AAV dsDNA, synthesized AAV dsDNA was
shown to be more stable under nondividing conditions, which
confirmed that dsDNA genome existed as extrachromosomal
episomes.
The amount of positive cells from ALP and LacZ staining at
various time points was quantified with AAV2 (Fig. 2 B and C) or
AAV8 (Fig. 2 D and E) vectors. In C2lacZ cells, both AAV2 and
AAV8 showed a similar transduction pattern. The amount of
LacZ-positive cells started to exceed ALP-positive cells 72 h after
infection. The percentage of LacZ-positive cells was 5% more
than ALP under nondividing conditions (P  0.05). Under dividing
conditions, there was a quick falling off in the amount ALP-positive
cells after day 3, whereas LacZ-positive cells remained at similar
level (P  0.05) and decisively more than ALP-positive cells. This
result confirmed the loss of newly formed AAV dsDNA under both
dividing and nondividing conditions and that the instability of
dsDNA intermediates may be a general issue for all of the AAV
serotypes.
Characterization of Instability of Transient AAV dsDNA Intermediates
in Vivo. To investigate AAV dsDNA intermediates in vivo,
ROSA26R mice were injected i.v. with an equal amount of AAV2-
Fig. 1. AAV genome footprinting strategy. (A) Schematic representation of
the AAV-CB-ALP and AAV-CB-cre vectors used in this work. The locations of
restriction enzymes and probe for Southern blotting are marked. PolyA, the
human -globin gene polyadenylation signal; s, stuffer sequence without
function; B, BglII; E, EcoRI. (B) Schematic of lacZ activation by Cre in C2lacZ cells
and ROSA26R (Gtrosa26tm1Sor) mice. (C) Strategy of AAV dsDNA footprint-
ing. Key steps are shown: 1, rAAV entry; 2, uncoating, dsDNA synthesis, lacZ
gene activation; 3, dsDNA get lost; 4, dsDNA stabilization. X stands for the stop
sequence in the lacZ gene expression cassette.











or AAV8-based vectors expressing ALP or cre reporter. Mouse
livers were harvested and analyzed for ALP and LacZ expression
at different time points after vector administration (Fig. 3A).
Consistent with previous studies, AAV2-ALP exhibited a slow,
increasing profile in transduction, reaching a plateau at week 6,
transducing 5% of hepatocytes. In contrast, the amount of
LacZ-positive liver cells continued to increase, and almost all cells
in the entire liver expressed lacZ gene at the end of the experi-
mental period. This result suggested that (i) AAV dsDNA was not
synthesized in a short period but continuously over the time of
transduction; (ii) nearly all liver cells were infected by AAV2
vectors and synthesized AAV dsDNA; (iii) the AAV dsDNA in all
cells must be competent for transcription and protein translation;
and (iv) only a small portion of synthesized dsDNA could be
stabilized.
In contrast, AAV8-mediated liver transduction exhibited a dif-
ferent pattern in ALP expression (Fig. 3B). The difference between
AAV2 and AAV8 transduction lies mainly on two aspects. First,
ALP- and LacZ-positive cells for AAV8-mediated transduction
appeared faster than AAV2. At day 3 and day 7, the differences in
both ALP and LacZ between AAV2 and AAV8 were remarkable,
which suggested that AAV8 could synthesize its dsDNA at a faster
pace. Because there is no difference in the vector DNA composi-
tion, this result suggested that AAV capsid contributed to these
differences. Second, the differences of ALP expression between
AAV2 and AAV8 remained remarkable at the end of the exper-
imental period. However, the differences in LacZ-positive cells
were reduced over time. A similar number of cells started to express
lacZ gene at week 8, suggesting that the same amount of liver cells
had received AAV2 and AAV8. Thus receptors are not the
obstacles for cells to be transduced by rAAV vectors. The differ-
ence in ALP and lacZ gene expression suggested that the synthe-
sized dsDNA degradation was the key factor.
To confirm that the differences between ALP and LacZ expres-
sion were not caused by the difference in viral genomes carrying
ALP and cre vectors, we analyzed the dsDNA genome by Southern
blotting. As shown in Fig. 3C, the amount of ds-ALP vector and
ds-cre vectors remained similar to each other throughout the
experimental period, which ruled out that there was a preference
for stabilizing rAAV genomes carrying the cre gene in the liver.
Consistent with the observation that AAV8 transduced more cells
than AAV2 at days 3 and 7, the detected rAAV genomes from
AAV8 at day 3 and day 7 were more than that of AAV2, which also
confirmed that AAV8 released/uncoated AAV genomes at a much
faster pace than AAV2.
AAV dsDNA Released from Self-Complementary AAV Vector (scAAV) Is
Not Stable. Because scAAV vectors release dsDNA instead of
ssDNA, they bypass the step to convert ssDNA into dsDNA. To
confirm that the instability of AAV dsDNA is the key factor
affecting rAAV transduction, we constructed scAAV-TTR-ALP
and scAAV-TTR-cre. The reporter genes are under the control of
the liver-specific transthyretin (TTR) promoter. After AAV2 vec-
tors were produced by using these two vector plasmids, they were
administered i.v. to ROSA26R mice at a ratio of 1:1. The expression
of ALP and LacZ was monitored and is presented in Fig. 4. Similar
to what was observed with AAV2 carrying ss genomes, the expres-
sion of ALP increased slowly and reached a peak in 8–10% of
liver cells at week 4–6. The LacZ expression was 10–20 times
more than ALP expression at earlier time points and reached 100%
Fig. 2. rAAV transduction in C2lacZ cells. C2lacZ cells were infected with
AAV-CB-ALP and AAV-CB-cre (1:1) at a multiplicity of infection of 10,000. The
expression of ALP or LacZ was analyzed at specified time points as indicated.
(A) ALP or LacZ expression of C2lacZ cells infected with AAV2 vectors. (Upper)
Nondividing C2lacZ cells. (Lower) Dividing C2lacZ cells. (Scale bar: 100 m.)
(B–E) Quantification of ALP- or LacZ-positive cells after AAV2 or AAV8 trans-
duction of C2lacZ cells. The y axis stands for the percentage of cells positive for
ALP or LacZ staining. Error bars indicate the SD values.
Fig. 3. AAV dsDNA footprinting in the liver. AAV2 or AAV8 carrying ALP or
cre was administered i.v. to ROSA26R mice at a dose of 1  1011 vector
genomes. (A) Staining of ALP or LacZ expression in the liver section of mice
receiving AAV2-based vectors at various time points after vector administra-
tion. Neg represents a negative control before vectors were administered.
(Scale bar: 100 m.) (B) Staining of ALP or LacZ expression in the liver section
of mice receiving AAV8-based vectors at various time points after vector
administration. (C) Southern blot analysis of rAAV genome after vector ad-
ministration. Total cellular mouse liver DNA was extracted from liver samples
of each time point. Twenty micrograms of BglII-, MfeI-, and EcoRV-digested
genomic DNA was separated on 0.8% agarose gel. Hybridization was per-
formed by using CB promoter probe recovered by EcoRI. Genome copy num-
ber standards are shown in the figure. Fragment size corresponding to the ALP
or cre vector is also indicated. ss represents the ssDNA from the incoming
vector.
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transduction at 4–6 weeks. Because there was no interference of
AAV ssDNA genomes, the results confirmed that the majority of
released dsDNA were transient and were not stabilized.
Stabilized rAAV Genomes Remained as Episomes in Vivo. To examine
the dsDNA integration that led to ALP and lacZ gene expression,
we performed partial hepatectomy on mice that had received
AAV-CB-ALP and AAV-CB-cre at week 6 after vector adminis-
tration. The partial hepatectomy is often used to stimulate liver
regeneration. The dividing hepatocytes would keep the integrated
AAV dsDNA and dilute/lose episomal AAV dsDNA. As shown in
Fig. 5, there was a significant drop in the number of ALP-positive
cells but not LacZ-positive cells. This result is consistent with the in
vitro data of C2lacZ cells, confirming that most of the stabilized
ALP gene from AAV dsDNA was present in nonintegrated epi-
somal form. Because the lacZ gene was in the chromosome that was
activated by Cre, it remained stable in nearly 100% of liver cells.
Discussion
The rAAV DNA undergoes a series of changes during the trans-
duction process. In the ssDNA stage, it exists as intact virion before
uncoating or as free ssDNA after uncoating. After ssDNA con-
version into dsDNA, it may exist as linear monomers, linear
concatemers, circular monomer, circular concatemers, or inte-
grated rAAV genomes. Here, we provide strong evidence on the
existence of two classes of dsDNA: stabilized dsDNA and newly
formed transient dsDNA. The transient form may come from
annealing or second-stranded DNA synthesis.
It is documented that only 5–10% of hepatocytes are permis-
sive to stable transduction with rAAV2 vectors, whereas rAAV8
could obtain almost 30% or more of stably transduced hepatocytes
with a high dose (21, 39). The transduction usually resulted in an
average of 0.5–2 copies of rAAV genomes per cell. Based on the
conventional vector dose of 1  101112 vector genomes per mouse,
99.9% of all input viral genomes were lost without contributing to
rAAV transduction (40, 41). Viral DNA loss could occur at any step
of its transduction, such as entry, translocation, uncoating, and
conversion from ssDNA into dsDNA. There are no previous studies
focusing on the stability of synthesized transient dsDNA genomes.
In this work, we overcame the technical difficulties and specifically
examined the stability of transient AAV dsDNA by using
ROSA26R mice and rAAV vector expressing the cre gene.
The primary discovery of this work is the existence of transient
functional dsDNA molecules in rAAV transduction. Because of
their transient nature, conventional direct methods such as South-
ern blotting are not effective for monitoring them. In this work, we
developed an assay to detect an often ignored AAV DNA species
in the rAAV transduction life cycle. As shown in Fig. 3C, Southern
blotting could not reveal the existence of this species because the
average life of the transient dsDNA would be short. Based on the
Southern blotting procedures, we estimated that the transient
dsDNA genome would not be detected by Southern blotting if its
half-life is only a couple of hours. In situ DNA hybridization is
another method that may directly monitor AAV dsDNA in vivo. It
has been demonstrated that only 5% of hepatocytes contained
AAV dsDNA at 5 weeks after transduction. The dsDNA detected
by this method was concomitant with the amount of cells expressing
transgene (42). Therefore, in situ hybridization also only detected
mostly stabilized dsDNA. Although the total amount of transient
dsDNA formed could be abundant, the number of transient
dsDNA would be rare compared with other intermediates of rAAV
genomes at a specific time point. As shown in Fig. 3, the transient
dsDNA formation is a dynamic process. It can be formed contin-
uously depending on the intracellular trafficking, uncoating, and
annealing/second-stranded DNA synthesis. The degradation/loss of
dsDNA appears to be coupled with its formation. Thus, at any
stage, either Southern blot analysis or in situ DNA hybridization can
only detect the stabilized dsDNA in addition to transient dsDNA
at that time point. Thus, only the ‘‘AAV dsDNA footprinting’’
technique can study the cumulative effects of transient dsDNA
genomes.
Because stabilized rAAV genomes are represented by ALP
expression, whether the amount of ALP expression is concomitant
with dsDNA is critical. Silent dsDNA genomes would make the
interpretation of the experiment results complicated. At similar
dose, AAV2 was reported to transduce 5% of liver cells. The in situ
DNA hybridization experiment reported that there were no silent
AAV dsDNA templates, establishing that only 5% of cells actually
harbored dsDNA (42), which is inconsistent with the ALP expres-
sion of our work. In addition, the promoter used for ALP expression
is derived from constitutive -actin or TTR promoter that has not
been reported to switch off in vivo. Finally, the number of positive
cells increased over the experiment period instead of decreasing,
which is in contrast to what is observed for promoter silence. Taken
together, promoter silence cannot be the prominent factor that
would complicate our data interpretation.
Our results will help address a misconception that AAV receptor
is the ultimate deciding factor for rAAV transduction efficacy. As
shown in Fig. 3, there is no difference between AAV2 and AAV8
in LacZ expression in the liver, which indicates that the ‘‘cumula-
tive’’ dsDNA formed are similar for AAV2 and AAV8. This finding
Fig. 4. Instability of scAAV genomes. Self-complementary AAV2 vectors
carrying TTR-ALP or TTR-cre (1:1) were administered i.v. to the ROSA26R mice
at a dose of 1  1011 vector genomes. Liver were harvested at various time
points after vector administration, and the ALP and lacZ gene expression was
analyzed by histochemical staining. Neg represents a negative control before
vectors were administered. (Scale bar: 100 m.)
Fig. 5. rAAV genomes remain mostly as episomes. ROSA26R mice were
injected with AAV-CB-ALP and AAV-CB-cre (1:1) at a dose of 1  1011 vector
genomes per animal through the tail vein. After 6 weeks, half of the mice (n 
3) underwent partial hepatectomy (PH). All animals were killed another 6
weeks later. ALP or LacZ staining of the liver sections before and after PH is
shown. Control mice receiving saline were subjected to the same PH proce-
dure. (Scale bar: 100 m.)











implies that the AAV-CB-cre vector has successfully gained entry
to almost all liver cells, uncoated, converted ssDNA into dsDNA,
and synthesized Cre protein, which subsequently activated the lacZ
gene. Even with a 10-fold lower dose, similar phenomena were also
observed (SI Fig. 8). This result is also in agreement with a previous
study showing a high percentage of liver cells infected by rAAV
vectors using DNA in situ hybridization (42). As a further step, we
demonstrated that all cells have functional rAAV genomes synthe-
sized, which were then later lost. Furthermore, our results also
confirmed that dsDNA were formed much faster for AAV8,
consistent with previous observations (21). Infection kinetics is
noticeably different between AAV2 and AAV8. How AAV ssDNA
is released is probably the key leading to difference in transduction
level between AAV2 and AAV8. Thus, the uncoating process may
have significantly impacted the stability of subsequently formed
dsDNA.
Our assays further confirmed that the majority of rAAV ge-
nomes remained as episomal DNA after transduction. Both in vitro
and in vivo results (Figs. 2 and 5) supported this conclusion. There
might be only a small amount of cells harboring integrated rAAV
genomes, which did not get lost during the host cell divisions. The
faster host cells divide, the more functional episomal dsDNA are
lost, which is also why rAAV often performs better in differentiated
cells (3, 4, 43). The combined results of this work and other studies
for rAAV transduction prompted us to propose a working model
for the rAAV transduction pathway (Fig. 6). As illustrated, there
are potential losses of rAAV genomes at all stages of rAAV
transduction: entry, intracellular trafficking, uncoating, and ssDNA
to dsDNA conversion. Because 100% cells showed LacZ expression
even at doses of 1  1010 vector genomes per mouse, these steps
appear not to be the deciding factor for rAAV transduction
efficiency. The ultimate deciding factor for transduction efficiency
is the amount of dsDNA intermediates stabilized. The loss of
dsDNA intermediates contributes to the differences in transduction
between AAV2 and AAV8. Although we emphasize the impor-
tance of dsDNA stability, the other steps such as vector receptor
binding, intracellular trafficking, and uncoating may still be differ-
ent and contribute to the kinetics of transient dsDNA, which
ultimately determines whether these transient dsDNA are stabi-
lized or degraded.
Our model is also supported by experimental evidence from the
most recently developed scAAV vectors (24, 44–48). Instead of
releasing ssDNA from uncoating, scAAV vectors release dsDNA
genomes. As shown in Fig. 4, releasing dsDNA genomes improved
the percentage of cells expressing ALP from 2–5% to 8–10%. But
there was still a significant difference between ALP and LacZ
expression. For ssAAV vector, 95% cells lost transient dsDNA
molecules. For scAAV vectors, 90% of cells lost dsDNA genomes.
Because ssAAV and scAAV vectors showed only 5% difference in
the transduction whereas AAV2 and AAV8 vectors showed 30–
80% difference, fast uncoating is confirmed to be a more efficient
way for stabilizing rAAV genomes.
It has been recognized that the ssDNA to dsDNA conversion is
a rate-limiting step for rAAV transduction (19, 20). Our previous
experiments demonstrated that second-stranded DNA synthesis
was a fast reaction (23). AAV footprinting confirmed that rather
than viral entry and transient dsDNA formation, the instability of
AAV transient dsDNA is the determinant for efficient rAAV
transduction. These seemly contradictive observations were recon-
ciled in Fig. 6. Because transient dsDNA was unknown in the
previous studies on second-stranded DNA synthesis, and Southern
blotting and conventional molecular biology techniques only de-
tected stabilized AAV dsDNA, a modified conclusion should be
that stabilized dsDNA formation is the rate-limiting step for rAAV
transduction. The stabilized dsDNA genomes were the combined
results from viral entry, translocation, uncoating, and viral DNA
degradation. Taken together, transient dsDNA is the decisive
intermediate in the rate-limiting step, and its stability dictates the
performance of rAAV transduction. Control of transient dsDNA
degradation will be the key pathway for improving rAAV trans-
duction efficacy.
Materials and Methods
Recombinant AAV Vector Production, Purification. All rAAV vectors
were produced by the triple-transfection method, which has been
described previously (49). Briefly, a vector plasmid (with AAV2
inverted terminal repeats), a helper plasmid (with the rep and cap
genes of AAV2 or AAV8), and mini adenovirus helper plasmid
(pF6, with essential regions from the adenovirus genome) were
cotransfected into 293 cells by calcium phosphate precipitation.
AAV particles were purified by cesium chloride gradient ultracen-
trifugation. The physical particle titers were determined by silver
staining and quantitative dot-blot assay.
AAV2 or AAV8 vectors carrying human placenta ALP or the cre
recombinase gene were cross-packaged with AAV2 or AAV8
helper plasmids by using AAV-CB-ALP or AAV-CB-cre as the
vector plasmid, respectively. Both ALP and cre genes are under the
control of CB. Both vectors are similar in size. Self-complementary
AAV2 vector carrying ALP or cre gene was produced by cross-
packaging AAV2 helper plasmid with scAAV-TTR-ALP or
scAAV-TTR-cre. ALP and cre gene are under the control of a
230-bp liver-specific TTR promoter because of the limited pack-
age capacity of scAAV2.
Establishment of C2lacZ Stable Cell Line. The plasmid pPGK-
neotpalox2-lacZ was a gift from Philippe Soriano (Fred Hutchinson
Cancer Research Center, Seattle, WA). Mouse myoblast cell line
C2C12 was purchased from American Type Culture Collection and
maintained in DMEM/10% FBS. Stable C2C12 cells carrying the
Fig. 6. Theoretical model for transient AAV dsDNA in rAAV transduction life
cycle. (A) Transient dsDNA status during AAV2 transduction. (B) Transient
dsDNA during AAV8 transduction. The difference between AAV2 and AAV8 in
uncoating is noted in the figure as ‘‘slow’’ and ‘‘fast.’’ The traditional rate-
limiting step is also noted in the figure. **, all of the steps that may involve
degradation. The vector DNA illustrated by dotted line represents lost AAV
genomes.
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loxP-regulated lacZ gene were generated by transfecting pPGK-
neotpalox2-lacZ into C2C12 cells, and they were selected under 400
g/ml G418. Resulting colonies were screened for LacZ expression
after pAAV-CB-cre plasmid transfection. The positive clone with
the highest level of LacZ expression was characterized further and
renamed as C2lacZ.
Histochemical Staining. To stain LacZ expression, cells or frozen
liver sections were fixed in PBS containing 2% formaldehyde and
0.2% glutaraldehyde at 4°C for 5 min. After being washed with PBS
three times, cells or liver sections were incubated at 37°C overnight
in PBS/5 mM potassium ferricyanide/5 mM potassium ferrocyanide/
2 mM MgCl2/1 mg/ml X-Gal.
To detect human placenta ALP activity, fixed cells or liver
sections were washed once in PBS, heat-inactivated in PBS at 70°C
for 30 min, and equilibrated in PBS containing 100 mM TrisHCl,
pH 9.5/100 mM NaCl/10 mM MgCl2 for 10 min. Subsequently, cells
or sections were stained at room temperature for 30 min with
nitroblue tetrazolium–5-bromo-4-chloro-3-indolyl phosphate
ready-to-use tablets (Roche, Indianapolis, IN).
rAAV Vector Infection in Vitro. C2lacZ cells were seeded at 50%
confluence in a 6-well plate. Twenty four hours later, AAV-CB-
ALP and AAV-CB-cre (1:1), at a dose of 5  109 vector genomes,
were mixed together and added to the wells. Histochemical staining
was performed at various time points. C2lacZ cells can be main-
tained under either dividing or differentiation conditions. Under
the differentiation condition (nondividing), cells were maintained
as confluent cell monolayers in reduced horse serum. Under the
dividing condition, cells were maintained in 10% FBS and passed
every other day. The cells maintained their active growth during the
experiment period. The ALP- or LacZ-positive cells were quanti-
fied from five random fields under 10 magnification with a
DIAPHOT 200 microscope (Nikon, Melville, NY).
Animal Procedures. ROSA26R (Gtrosa26tm1Sor) mice were pur-
chased from the Jackson Laboratory (Bar Harbor, ME). Six- to
eight-week-old male mice were used for the experiments. All of the
animal experiments were performed according to the Children’s
Hospital of Philadelphia animal guidelines.
AAV-CB-ALP and AAV-CB-cre (1:1), at a dose of 1  1011
vector genomes, were mixed together in 0.9% NaCl to a final
volume of 200 l and injected into the mouse through the tail vein.
Livers were harvested and analyzed at day 3, day 7, week 2, week
4, week 6, and week 8 after vector administration. The harvested
liver tissues were embedded in Tissue-Tek optimal cutting temper-
ature compound (Sakura Finetek, Torrance, CA) and frozen in dry
ice. Twenty-micrometer sections were cut and stained to detect
LacZ and ALP expression as described above. After staining,
sections were dehydrated with xylene, mounted with Cytoseal 60
mounting medium (Richard-Allan Scientific, Kalamazoo, MI), and
protected with covering slides. Pictures were taken under an Eclipse
E800 microscope (Nikon).
For partial hepatectomy, animals receiving vectors after 6 weeks
were anesthetized by 2 liters of oxygen/2% Forane per min. Partial
hepatectomy was performed according to the method of Higgins
and Anderson (50), and animals were killed 6 weeks after the
procedure. Livers were harvested, and ALP or LacZ staining was
performed as described above.
Southern Blot Analysis. Twenty micrograms of total cellular DNA
from AAV-transduced cells or livers was digested with BglII, MfeI,
and EcoRV, and Southern blotting was performed by using CB
DNA probe, which was an 800-bp EcoRI fragment labeled with
[-32P]dCTP. The vector genome copy number standards were
prepared by adding an equivalent number of corresponding plasmid
molecules to 20 g of total DNA extracted from control cells.
Statistical Analysis. Data were described by using mean  SD
whenever appropriate. ANOVA was performed to analyze differ-
ences among the groups. A P value of 0.05 was considered to be
statistically significant.
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